Why the study?
Are plasma levels of PAI-1 elevated in subjects with white coat hypertension compared to healthy controls and sustained hypertension?
Are plasma levels of PAI-1 elevated in subjects with white coat hypertension compared to healthy controls and sustained hypertension?
Patients with white coat hypertension have intermediate PAI-1 levels between healthy controls and sustained hypertension, suggesting a potential mechanism for increased cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May indicate intermediate CV risk in white coat hypertension; hypothesis-generating for PAI-1 as biomarker, needing prospective validation.
High plasminogen activator inhibitor-1 (PAI-1) levels are potential risk factors for cardiovascular disease. The risk profile of white coat hypertension (WCHT) has not yet been completely clear. In this study, we aimed to determine the plasma levels of PAI-1, markers of fibrinolysis and increased cardiovascular disease risk, in a group with WCHT and to obtain clinical results by comparing WCHT group with hypertensive and healthy groups. Age and sex matched 30 patients with WCHT, 30 patients with sustained hypertension, and 30 healthy subjects were included in the study. The plasma levels of PAI-1 were significantly higher in sustained hypertension group than in WCHT group (p < 0.01). There were significantly higher levels in patients with WCHT than in control group (p < 0.01). Our data suggests one possible mechanism by which WCHT subjects may be at increased cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Çoban et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: